Citius Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to acquiring, developing and commercializing adjunctive cancer care and critical care drug products, announced it was discontinuing Suprenza, its FDA-approved phentermine-based product for weight loss.
[adsense:336x280:8701650588]
Myron Holubiak, CEO of Citius said, "Suprenza no longer meets our core strategic objectives. We are dedicating our focus on our phase 3 asset Mino-Lok and our phase 2b asset Hydro-Lido for hemorrhoids."
[adsense:468x15:2204050025]
Holubiak continued, "We feel that the obesity and weight management market has shifted and therefore we are devoting our efforts on developing our leading two assets. We anticipate a minimal financial impact to Citius from discontinuation since we eliminate our ongoing regulatory expenses and have not historically received royalties from the product."
